{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:54:56Z","timestamp":1772164496977,"version":"3.50.1"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Purpose: In contrast to the numerous broad screens for oncogene mutations in adult cancers, few such screens have been conducted in pediatric solid tumors. To identify novel mutations and potential therapeutic targets in pediatric cancers, we conducted a high-throughput Sequenom-based analysis in large sets of several major pediatric solid cancers, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma (RMS), and desmoplastic small round cell tumor (DSRCT).<\/jats:p>\n                  <jats:p>Experimental Design: We designed a highly multiplexed Sequenom-based assay to interrogate 275 recurrent mutations across 29 genes. Genomic DNA was extracted from 192 neuroblastoma, 75 Ewing sarcoma, 89 RMS, and 24 DSRCT samples. All mutations were verified by Sanger sequencing.<\/jats:p>\n                  <jats:p>Results: Mutations were identified in 13% of neuroblastoma samples, 4% of Ewing sarcoma samples, 21.1% of RMS samples, and no DSRCT samples. ALK mutations were present in 10.4% of neuroblastoma samples. The remainder of neuroblastoma mutations involved the BRAF, RAS, and MAP2K1 genes and were absent in samples harboring ALK mutations. Mutations were more common in embryonal RMS (ERMS) samples (28.3%) than alveolar RMS (3.5%). In addition to previously identified RAS and FGFR4 mutations, we report for the first time PIK3CA and CTNNB1 (\u03b2-catenin) mutations in 5% and 3.3% of ERMS, respectively.<\/jats:p>\n                  <jats:p>Conclusions: In ERMS, Ewing sarcoma, and neuroblastoma, we identified novel occurrences of several oncogene mutations recognized as drivers in other cancers. Overall, neuroblastoma and ERMS contain significant subsets of cases with nonoverlapping mutated genes in growth signaling pathways. Tumor profiling can identify a subset of pediatric solid tumor patients as candidates for kinase inhibitors or RAS-targeted therapies. Clin Cancer Res; 18(3); 748\u201357. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-11-2056","type":"journal-article","created":{"date-parts":[[2011,12,6]],"date-time":"2011-12-06T00:41:21Z","timestamp":1323132081000},"page":"748-757","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":192,"title":["Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways"],"prefix":"10.1158","volume":"18","author":[{"given":"Neerav","family":"Shukla","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pediatrics and 2Pathology, 3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 4Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"}]},{"given":"Nabahet","family":"Ameur","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pediatrics and 2Pathology, 3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 4Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"}]},{"given":"Ismail","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pediatrics and 2Pathology, 3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 4Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"}]},{"given":"Khedoudja","family":"Nafa","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pediatrics and 2Pathology, 3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 4Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"}]},{"given":"Chyau-Yueh","family":"Lau","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pediatrics and 2Pathology, 3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 4Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"}]},{"given":"Angela","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pediatrics and 2Pathology, 3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 4Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"}]},{"given":"Laetitia","family":"Borsu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pediatrics and 2Pathology, 3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 4Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"}]},{"given":"Frederic G.","family":"Barr","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pediatrics and 2Pathology, 3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 4Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"}]},{"given":"Marc","family":"Ladanyi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pediatrics and 2Pathology, 3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 4Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"},{"name":"Authors' Affiliations: Departments of 1Pediatrics and 2Pathology, 3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 4Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania"}]}],"member":"1086","published-online":{"date-parts":[[2012,1,31]]},"reference":[{"key":"2022061023392285000_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"2022061023392285000_bib2","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022061023392285000_bib3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"2022061023392285000_bib4","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061023392285000_bib5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature07397","article-title":"Activating mutations in ALK provide a therapeutic target in neuroblastoma","volume":"455","author":"George","year":"2008","journal-title":"Nature"},{"key":"2022061023392285000_bib6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature07398","article-title":"Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma","volume":"455","author":"Janoueix-Lerosey","year":"2008","journal-title":"Nature"},{"key":"2022061023392285000_bib7","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-06-0433","article-title":"Mutation analysis of 24 known cancer genes in the NCI-60 cell line set","volume":"5","author":"Ikediobi","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2022061023392285000_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/ng1975","article-title":"High-throughput oncogene mutation profiling in human cancer","volume":"39","author":"Thomas","year":"2007","journal-title":"Nat Genet"},{"key":"2022061023392285000_bib9","doi-asserted-by":"crossref","first-page":"e7887","DOI":"10.1371\/journal.pone.0007887","article-title":"Profiling critical cancer gene mutations in clinical tumor samples","volume":"4","author":"MacConaill","year":"2009","journal-title":"PLoS One"},{"key":"2022061023392285000_bib10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/jmg.2007.050450","article-title":"Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS\/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome","volume":"44","author":"Nava","year":"2007","journal-title":"J Med Genet"},{"key":"2022061023392285000_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1126\/science.1124642","article-title":"Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome","volume":"311","author":"Rodriguez-Viciana","year":"2006","journal-title":"Science"},{"key":"2022061023392285000_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MPH.0b013e31805d8f57","article-title":"Rhabdomyosarcoma in a patient with Noonan syndrome phenotype and review of the literature","volume":"29","author":"Moschovi","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"2022061023392285000_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive Ras in developmental disorders and cancer","volume":"7","author":"Schubbert","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2022061023392285000_bib14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JCO.2005.02.081","article-title":"Ewing sarcomas with p53 mutation or p16\/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse","volume":"23","author":"Huang","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061023392285000_bib15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","article-title":"Identification of ALK as a major familial neuroblastoma predisposition gene","volume":"455","author":"Mosse","year":"2008","journal-title":"Nature"},{"key":"2022061023392285000_bib16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00442704","article-title":"Incidence of ras gene mutations in neuroblastoma","volume":"147","author":"Ballas","year":"1988","journal-title":"Eur J Pediatr"},{"key":"2022061023392285000_bib17","first-page":"6324","article-title":"Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction","volume":"49","author":"Stratton","year":"1989","journal-title":"Cancer Res"},{"key":"2022061023392285000_bib18","first-page":"1596","article-title":"Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers","volume":"51","author":"Moley","year":"1991","journal-title":"Cancer Res"},{"key":"2022061023392285000_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0344-0338(98)80016-2","article-title":"p53 and ras mutations in Ewing's sarcoma","volume":"194","author":"Radig","year":"1998","journal-title":"Pathol Res Pract"},{"key":"2022061023392285000_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/(SICI)1098-2264(199908)25:4<399::AID-GCC14>3.0.CO;2-X","article-title":"Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma","volume":"25","author":"Blaker","year":"1999","journal-title":"Genes Chromosomes Cancer"},{"key":"2022061023392285000_bib21","first-page":"1269","article-title":"Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms","volume":"12","author":"Miao","year":"2004","journal-title":"Oncol Rep"},{"key":"2022061023392285000_bib22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/sj.leu.2403589","article-title":"Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia","volume":"19","author":"Gustafsson","year":"2005","journal-title":"Leukemia"},{"key":"2022061023392285000_bib23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/gcc.20322","article-title":"Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies","volume":"45","author":"Chen","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"2022061023392285000_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2407-6-177","article-title":"Mutations in PIK3CA are infrequent in neuroblastoma","volume":"6","author":"Dam","year":"2006","journal-title":"BMC Cancer"},{"key":"2022061023392285000_bib25","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2005.04.4974","article-title":"Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations","volume":"24","author":"Thompson","year":"2006","journal-title":"J Clin Oncol"},{"key":"2022061023392285000_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/modpathol.3800977","article-title":"Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations","volume":"21","author":"Curia","year":"2008","journal-title":"Mod Pathol"},{"key":"2022061023392285000_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/path.2514","article-title":"Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics","volume":"218","author":"Fattet","year":"2009","journal-title":"J Pathol"},{"key":"2022061023392285000_bib28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/gcc.20702","article-title":"RAS signaling dysregulation in human embryonal Rhabdomyosarcoma","volume":"48","author":"Martinelli","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"2022061023392285000_bib29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/gcc.20864","article-title":"High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis","volume":"50","author":"Paulson","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"2022061023392285000_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ijc.2910350513","article-title":"N-ras gene activation in the RD human rhabdomyosarcoma cell line","volume":"35","author":"Chardin","year":"1985","journal-title":"Int J Cancer"},{"key":"2022061023392285000_bib31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/0008-5472.CAN-09-1851","article-title":"Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas","volume":"70","author":"Schiffman","year":"2010","journal-title":"Cancer Res"},{"key":"2022061023392285000_bib32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ng.619","article-title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","volume":"42","author":"Barretina","year":"2010","journal-title":"Nat Genet"},{"key":"2022061023392285000_bib33","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.4161\/cc.8.9.8255","article-title":"PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches","volume":"8","author":"Ligresti","year":"2009","journal-title":"Cell Cycle"},{"key":"2022061023392285000_bib34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/sj.bjc.6603952","article-title":"PDK-1\/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound","volume":"97","author":"Cen","year":"2007","journal-title":"Br J Cancer"},{"key":"2022061023392285000_bib35","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1158\/0008-5472.CAN-08-1712","article-title":"Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody","volume":"68","author":"Cao","year":"2008","journal-title":"Cancer Res"},{"key":"2022061023392285000_bib36","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"2022061023392285000_bib37","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1600-0463.2008.00914.x","article-title":"Beta-catenin expression and mutation in adult and pediatric Wilms' tumors","volume":"116","author":"Su","year":"2008","journal-title":"APMIS"},{"key":"2022061023392285000_bib38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2350\/08-11-0553.1","article-title":"Beta-catenin mutation does not seem to have an effect on the tumorigenesis of pediatric rhabdomyosarcomas","volume":"12","author":"Bouron-Dal Soglio","year":"2009","journal-title":"Pediatr Dev Pathol"},{"key":"2022061023392285000_bib39","first-page":"3395","article-title":"Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models","volume":"119","author":"Taylor","year":"2009","journal-title":"J Clin Invest"},{"key":"2022061023392285000_bib40","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"2022061023392285000_bib41","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"key":"2022061023392285000_bib42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"2022061023392285000_bib43","doi-asserted-by":"crossref","first-page":"e6833","DOI":"10.1371\/journal.pone.0006833","article-title":"Mutational profile of GNAQQ209 in human tumors","volume":"4","author":"Lamba","year":"2009","journal-title":"PLoS One"},{"key":"2022061023392285000_bib44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00381-010-1264-1","article-title":"IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group","volume":"27","author":"Pollack","year":"2011","journal-title":"Childs Nerv Syst"},{"key":"2022061023392285000_bib45","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/leu.2010.56","article-title":"Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study","volume":"24","author":"Ho","year":"2010","journal-title":"Leukemia"},{"key":"2022061023392285000_bib46","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J Pathol"},{"key":"2022061023392285000_bib47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"2022061023392285000_bib48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11523-011-0176-7","article-title":"Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs","volume":"6","author":"Ogita","year":"2011","journal-title":"Target Oncol"},{"key":"2022061023392285000_bib49","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1158\/0008-5472.CAN-07-6186","article-title":"Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors","volume":"68","author":"McDermott","year":"2008","journal-title":"Cancer Res"},{"key":"2022061023392285000_bib50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/18\/3\/748\/2008183\/748.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/18\/3\/748\/2008183\/748.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T05:18:25Z","timestamp":1654924705000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/18\/3\/748\/77637\/Oncogene-Mutation-Profiling-of-Pediatric-Solid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,31]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,1,31]]},"published-print":{"date-parts":[[2012,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-2056","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.22443372.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.22443372","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6519801","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.c.6519801.v1","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.13464956.14843055","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,31]]}}}